Physician profile
David Van
NPI 1760061493
$2,023.61
in general payments reported to CMS, 2019-2025
11 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.57 · 2023: $120 · 2024: $794 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.60 |
| Education | $153.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $640.70 | 2024-2025 | Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $327.85 | 2022-2025 | Cuvitru, Takhzyro |
| Genzyme Corporation | $300.67 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $190.87 | 2025 | Dupixent |
| Biocryst US Sales Co., LLC | $159.91 | 2024-2025 | Orladeyo |
| Genentech USA, INC. | $113.22 | 2024 | Xolair |
| Csl Behring | $89.62 | 2024-2025 | Hizentra, Andembry |
| Glaxosmithkline, LLC. | $77.90 | 2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $58.78 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.18 | 2024-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $14.91 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.